Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Ovarian Cancer Diagnostics And Therapeutics Market: By Cancer Type: Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Others; By Modality: Diagnosis, Therapeutics; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Value Chain Analysis; Competitive Landscape; Industry Events and Developments

Global Ovarian Cancer Diagnostics and Therapeutics Market Outlook

The global ovarian cancer diagnostics and therapeutics market is projected to expand at a CAGR of 9.7% during the forecast period of 2022-2027.

 

Global Ovarian Cancer Diagnostics and Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The growing geriatric population and increased awareness among people are driving the growth of the diagnostic and therapeutic industry for ovarian cancer globally.

 

Properties and Applications

Ovarian cancer is the fourth most prevalent cause of death from cancer in females worldwide, and the tenth most prevalent cancer among females in the U.S. Ovarian cancer incidences are high in females belonging to the age group of 54-65 years. Pelvic, bloating, and abdominal pain, eating trouble, and urinary symptoms are the main causes of ovarian cancer.

Ovarian diagnostics and therapeutics are used to detect, treat, and heal ovarian cancer. The global ovarian cancer diagnostics and therapeutics industry can be segmented into cancer type and modality.

The industry is divided based on its cancer type as epithelial ovarian tumours and ovarian germ cell tumours, among others.

 

Global Ovarian Cancer Diagnostics and Therapeutics Market By Cancer Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The industry is broadly categorised based on its modality into:

  • Diagnosis
  • Biopsy
  • Blood Tests
  • Ultrasound
  • PET
  • CT Scan
  • Others
  • Therapeutics     
  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Hormonal Therapy
  • Others

The EMR report looks into the regional markets of ovarian cancer diagnostics and therapeutics like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.

 

Global Ovarian Cancer Diagnostics and Therapeutics Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The increasing incidences of ovarian cancer worldwide, the use of combination therapies for the treatment of ovarian cancer, and the rising geriatric population are some of the major factors accelerating the growth of the ovarian cancer diagnostics and therapeutics industry globally. The absence of accurate techniques to diagnose ovarian cancer and the lack of awareness regarding cancer detection and treatment in emerging and low-income economies are the major drawbacks that may affect the industry growth over the forecast period.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global ovarian cancer diagnostics and therapeutics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • AstraZeneca plc
  • C.H. Boehringer Sohn AG & Ko. KG
  • Bristol Myers Squibb Company
  • Eli Lilly And Company
  • F. Hoffmann-La Roche AG
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

REPORT FEATURES DETAILS
Base Year 2020
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Cancer Type, Modality, Region
Breakup by Cancer Type Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Others
Breakup by Modality Diagnosis, Therapeutics
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered AstraZeneca plc, C.H. Boehringer Sohn AG & Ko. KG, Bristol Myers Squibb Company, Eli Lilly And Company, F. Hoffmann-La Roche AG, Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always strive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Ovarian Cancer Diagnostics and Therapeutics Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Ovarian Cancer Diagnostics and Therapeutics Historical Market (2017-2021) 
    8.3    Global Ovarian Cancer Diagnostics and Therapeutics Market Forecast (2022-2027)
    8.4    Global Ovarian Cancer Diagnostics and Therapeutics Market by Cancer Type
        8.4.1    Epithelial Ovarian Tumors
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    Ovarian Germ Cell Tumors
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    Others
    8.5    Global Ovarian Cancer Diagnostics and Therapeutics Market by Modality
        8.5.1    Diagnosis
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
            8.5.1.1    Breakup by Type
                8.5.1.1.1    Biopsy
                    8.5.1.1.1.1     Market Share
                    8.5.1.1.1.2     Historical Trend (2017-2021)
                    8.5.1.1.1.3     Forecast Trend (2022-2027)
                8.5.1.1.2    Blood Tests
                    8.5.1.1.2.1    Market Share
                    8.5.1.1.2.2     Historical Trend (2017-2021)
                    8.5.1.1.2.3     Forecast Trend (2022-2027)
                8.5.1.1.3    Ultrasound
                    8.5.1.1.3.1    Market Share
                    8.5.1.1.3.2     Historical Trend (2017-2021)
                    8.5.1.1.3.3     Forecast Trend (2022-2027)
                8.5.1.1.4    PET
                    8.5.1.1.4.1    Market Share
                    8.5.1.1.4.2     Historical Trend (2017-2021)
                    8.5.1.1.4.3     Forecast Trend (2022-2027)
                8.5.1.1.5    CT Scan 
                    8.5.1.1.5.1    Market Share
                    8.5.1.1.5.2     Historical Trend (2017-2021)
                    8.5.1.1.5.3     Forecast Trend (2022-2027)
                8.5.1.1.6    Others
        8.5.2    Therapeutics
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
            8.5.2.4    Breakup by Type
                8.5.2.4.1    Chemotherapy
                    8.5.2.4.1.1     Market Share
                    8.5.2.4.1.2     Historical Trend (2017-2021)
                    8.5.2.4.1.3     Forecast Trend (2022-2027)
                8.5.2.4.2    Radiation Therapy
                    8.5.2.4.2.1    Market Share
                    8.5.2.4.2.2     Historical Trend (2017-2021)
                    8.5.2.4.2.3     Forecast Trend (2022-2027)
                8.5.2.4.3    Immunotherapy
                    8.5.2.4.3.1    Market Share
                    8.5.2.4.3.2     Historical Trend (2017-2021)
                    8.5.2.4.3.3     Forecast Trend (2022-2027)
                8.5.2.4.4    Hormonal Therapy
                    8.5.2.4.4.1    Market Share
                    8.5.2.4.4.2     Historical Trend (2017-2021)
                    8.5.2.4.4.3     Forecast Trend (2022-2027)
                8.5.2.4.5    Others
    8.6    Global Ovarian Cancer Diagnostics and Therapeutics Market by Region
        8.6.1    Market Share
            8.6.1.1    North America
            8.6.1.2    Europe
            8.6.1.3    Asia Pacific
            8.6.1.4    Latin America
            8.6.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country 
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    Key Indicators for Demand
    10.4    Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    AstraZeneca plc
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    C.H. Boehringer Sohn AG & Ko. KG
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Bristol Myers Squibb Company
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    Eli Lilly and Company
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    F. Hoffmann-La Roche AG
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Certifications
        12.2.6    Others
13    Industry Events and Developments


List of Key Figures and Tables

1.    Global Ovarian Cancer Diagnostics and Therapeutics Market: Key Industry Highlights, 2017 and 2027
2.    Global Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Cancer Type (USD Million), 2017-2021
3.    Global Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Cancer Type (USD Million), 2022-2027
4.    Global Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Modality (USD Million), 2017-2021
5.    Global Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Modality (USD Million), 2022-2027
6.    Global Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Region (USD Million), 2017-2021
7.    Global Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Region (USD Million), 2022-2027
8.    North America Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2021
9.    North America Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2022-2027
10.    Europe Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2021
11.    Europe Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2022-2027
12.    Asia Pacific Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2021
13.    Asia Pacific Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2022-2027
14.    Latin America Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2021
15.    Latin America Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2022-2027
16.    Middle East and Africa Ovarian Cancer Diagnostics and Therapeutics Historical Market: Breakup by Country (USD Million), 2017-2021
17.    Middle East and Africa Ovarian Cancer Diagnostics and Therapeutics Market Forecast: Breakup by Country (USD Million), 2022-2027
18.    Global Ovarian Cancer Diagnostics and Therapeutics Market Structure

Key Questions Answered in the Report

The global ovarian cancer diagnostics and therapeutics market is projected to grow at a CAGR of nearly 9.7% in the forecast period of 2022-2027.

The major drivers of the industry include the rising disposable incomes, increasing population, rising geriatric population, and the rising awareness about the cancer and its treatments among people.

The increased government funding and the surge in health care expenditure are expected to be the key trends guiding the growth of the industry.

North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market.

The major cancer types in the industry include epithelial ovarian tumours and ovarian germ cell tumours, among others.

Diagnosis and therapeutics are the leading modality segments in the industry.

The leading players in the market are AstraZeneca plc, Boehringer Ingelheim, Bristol Myers Squibb Company, Eli Lilly And Company, Hoffman-La Roche Ltd, GlaxoSmithKline Plc, and Johnson And Johnson, among others.

Analyst Review

The global ovarian cancer diagnostics and therapeutics market is being driven by the rising geriatric population. Aided by the rising incidences of cancer worldwide, the industry is expected to witness a healthy growth in the forecast period of 2022-2027, growing at a CAGR of 9.7%.

EMR’s meticulous research methodology delves deep into the industry, covering the macro and micro aspects of the industry. Based on cancer type, the market can be segmented into epithelial ovarian tumours and ovarian germ cell tumours, among others. On the basis of modality, the industry can be divided into diagnosis and therapeutics. The major regional markets of ovarian cancer diagnostics and therapeutics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above industry include AstraZeneca plc, C.H. Boehringer Sohn AG & Ko. KG, Bristol Myers Squibb Company, Eli Lilly And Company, F. Hoffmann-La Roche AG, Others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER